Reboxetine in seasonal affective
disorder: an open trial

by
Hilger E, Willeit M, Praschak-Rieder N,
Stastny J, Neumeister A, Kasper S
Department of General Psychiatry,
University of Vienna Waehringer Guertel 18-20 A-1090,
Vienna, Austria
Eur Neuropsychopharmacol 2001 Feb; 11(1):1-5


ABSTRACT

Seasonal affective disorder (SAD), winter type, is a condition characterized by the annual recurrence of depressive episodes during fall/winter, alternating with spring/summer euthymia or hypomania. Various neurotransmitters have been implicated in the etiology of SAD, the strongest evidence involving serotonin. Recently, increasing attention has been paid to the potential role of catecholaminergic pathways in the pathophysiology of SAD. We investigated the efficacy and tolerability of reboxetine, a selective noradrenaline inhibitor, in patients with SAD. Eleven out of sixteen patients who were included in a 6-week drug surveillance during winter season experienced full remission of depressive symptoms. Nine patients reported a rapid relief of preexistent severe atypical depressive symptoms within the first treatment week. Reboxetine might therefore be an effective and well-tolerated treatment option for SAD patients. In conclusion, our preliminary results are in line with evidence from recent studies suggesting that catecholaminergic systems might also be involved in the pathophysiology of SAD.


Efficacy
Reboxetine
Noradrenaline
NARIs and SSRIs
Reboxetine: structure
Reboxetine and the rat
Reboxetine and the elderly
Reboxetine versus fluoxetine
Reboxetine and major depression
Reboxetine and social functioning
Depression, antidepressants and noradrenaline





Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family